<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63793">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945437</url>
  </required_header>
  <id_info>
    <org_study_id>Mg_TKA</org_study_id>
    <nct_id>NCT01945437</nct_id>
  </id_info>
  <brief_title>Magnesium and TKA Pain</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that in staged bilateral total knee arthroplasty (TKA,
      magnesium sulfate administered during the perioperative period of the first TKA may decrease
      pain after the second TKA. It is known that pain is greater in the second TKA than in the
      first. Therefore, we compared pain of the second TKA between the magnesium and control
      groups.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>from the end of the TKA until 48 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain measured with visual analogue scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>analgesic</measure>
    <time_frame>from the end of the TKA until 48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>analgesic consumptions from the end of the TKA until 48 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group receive same volume of normal saline as in the magnesium group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group receive magnesium sulfate perioperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>The magnesium group receive intravenous magnesium sulfate.</description>
    <arm_group_label>magnesium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: American society of anesthesiologist physical status 1 - 2. patients
        scheduled to undergo staged bilateral TKA

        Exclusion Criteria: American society of anesthesiologist physical status &gt;3

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 13, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Kim Mihyun</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
